Countries around the world could come together to fund a global pull incentive, worth around $4.2bn, to encourage the development of new antibiotics, according to a new industry-sponsored report that says the need for international action on antimicrobial resistance (AMR) is increasingly urgent.
How To Make International Pull Incentives Work In Fight Against AMR
Global action on delivering pull incentives for the development of new antibiotics is urgently required, according to a new report that sets out how countries could join together to make incentives attractive enough for companies to invest in this space.
More from International
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
• By
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
More from Geography
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.